Ovarian cancer is often asymptomatic and is diagnosed at an advanced stage with poor survival rates, thus there is an urgent need to develop biomarkers for earlier detection of ovarian cancer. In the present study, we demonstrate for the first time that the previously reported metastasis-inducing protein AGR2 (anterior gradient protein 2) can be detected in the blood of ovarian cancer patients. Using a newly developed ELISA, we show significantly increased concentrations of AGR2 protein in plasma from cancer patients relative to normal controls. Plasma AGR2 concentrations were highest in stages II and III ovarian cancer patients and were similarly elevated in patients with both serous and non-serous tumours. The identification of elevated plasma concentrations of AGR2 may provide a useful biomarker to aid in the discrimination of normal and ovarian cancer patients particularly when used in combination with CA125.
Skip Nav Destination
Article navigation
Research Article|
March 30 2010
Increased plasma concentrations of anterior gradient 2 protein are positively associated with ovarian cancer
Tracey A. Edgell;
Tracey A. Edgell
*HealthLinx Ltd, 576 Swan Street, Richmond, Victoria 3121, Australia
Search for other works by this author on:
Dong L. Barraclough;
Dong L. Barraclough
†School of Clinical Sciences, University of Liverpool, Daulby Street, Liverpool L69 3GA, U.K.
‡School of Biological Sciences, University of Liverpool, Daulby Street, Liverpool L69 3GA, U.K.
Search for other works by this author on:
Antonio Rajic;
Antonio Rajic
*HealthLinx Ltd, 576 Swan Street, Richmond, Victoria 3121, Australia
Search for other works by this author on:
Janu Dhulia;
Janu Dhulia
*HealthLinx Ltd, 576 Swan Street, Richmond, Victoria 3121, Australia
Search for other works by this author on:
Kate J. Lewis;
Kate J. Lewis
*HealthLinx Ltd, 576 Swan Street, Richmond, Victoria 3121, Australia
Search for other works by this author on:
Jane E. Armes;
Jane E. Armes
§Mater Pathology, Mater Health Services, Brisbane, Queensland 4101, Australia
Search for other works by this author on:
Roger Barraclough;
Roger Barraclough
§Mater Pathology, Mater Health Services, Brisbane, Queensland 4101, Australia
Search for other works by this author on:
Philip S. Rudland;
Philip S. Rudland
§Mater Pathology, Mater Health Services, Brisbane, Queensland 4101, Australia
Search for other works by this author on:
Gregory E. Rice;
Gregory E. Rice
*HealthLinx Ltd, 576 Swan Street, Richmond, Victoria 3121, Australia
∥Baker IDI Heart and Diabetes Institute, 75 Commercial Road, Melbourne, Victoria 3134, Australia
Search for other works by this author on:
Dominic J. Autelitano
*HealthLinx Ltd, 576 Swan Street, Richmond, Victoria 3121, Australia
Correspondence: Dr Dominic J. Autelitano (email [email protected]).
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
October 21 2009
Revision Received:
February 02 2010
Accepted:
February 05 2010
Accepted Manuscript online:
February 05 2010
Online ISSN: 1470-8736
Print ISSN: 0143-5221
© The Authors Journal compilation © 2010 Biochemical Society
2010
Clin Sci (Lond) (2010) 118 (12): 717–725.
Article history
Received:
October 21 2009
Revision Received:
February 02 2010
Accepted:
February 05 2010
Accepted Manuscript online:
February 05 2010
Connected Content
A correction has been published:
Increased plasma concentrations of anterior gradient 2 protein are positively associated with ovarian cancer
Citation
Tracey A. Edgell, Dong L. Barraclough, Antonio Rajic, Janu Dhulia, Kate J. Lewis, Jane E. Armes, Roger Barraclough, Philip S. Rudland, Gregory E. Rice, Dominic J. Autelitano; Increased plasma concentrations of anterior gradient 2 protein are positively associated with ovarian cancer. Clin Sci (Lond) 1 June 2010; 118 (12): 717–725. doi: https://doi.org/10.1042/CS20090537
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
Open Access for all
We offer compliant routes for all authors from 2025. With library support, there will be no author nor reader charges in 5 journals. Check here |
![]() |